Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese firm simultaneously announces that it has inked a monoclonal antibody discovery deal with Xoma.
Advertisement

Related Content

Takeda Expands Antibody Collaboration With Xoma
Takeda Expands Antibody Collaboration With Xoma
Takeda Expands Antibody Collaboration With Xoma
Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec
Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec
Schering-Plough Expands Antibody Collaboration With Xoma
Takeda Drops Phase II Diabetes Drug
Takeda Drops Phase II Diabetes Drug
Takeda/BioNumerik’s Tavocept Phase III Data Did Not Meet Primary Endpoints
Takeda’s Combo Duetact Will Launch Later This Year For Type 2 Diabetes

Topics

Advertisement
UsernamePublicRestriction

Register

PS063398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel